IDH1 and glioblastoma: Nongenetic biomarkers, such as O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status, were not included in the 2021 WHO classification but are considered strong prognostic predictors [12] and should be performed on glioblastoma, IDH-wildtype.